PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmjdrcBMJ Open Diabetes Research & CareVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
BMJ Open Diabetes Res Care. 2017; 5(1): e000391corr1.
Published online 2017 September 7. doi:  10.1136/bmjdrc-2017-000391corr1
PMCID: PMC5595186

Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

Kitada M, Shin-ichi T, Konishi K et al. Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner. BMJ Open Diabetes Res Care 2017;5:e000391. doi:10.1136/bmjdrc-2017-000391.

The funding statement has been amended to: This work was financially supported by a grant from the Kidney Foundation, Japan and SANWA KAGAKU KENKYUSHO CO, LTD to DK.


Articles from BMJ Open Diabetes Research & Care are provided here courtesy of BMJ Publishing Group